Medamarin may be available in the countries listed below.
Ingredient matches for Medamarin
Lansoprazole
Lansoprazole is reported as an ingredient of Medamarin in the following countries:
- Vietnam
International Drug Name Search
Saturday, 24 October 2009
Sunday, 18 October 2009
Gen-Amantadine
Gen-Amantadine may be available in the countries listed below.
Ingredient matches for Gen-Amantadine
Amantadine
Amantadine hydrochloride (a derivative of Amantadine) is reported as an ingredient of Gen-Amantadine in the following countries:
- Canada
International Drug Name Search
Friday, 16 October 2009
Cambia
Cambia is a brand name of diclofenac, approved by the FDA in the following formulation(s):
CAMBIA (diclofenac potassium - for solution; oral)
Manufacturer: NAUTILUS NEUROSCIENC
Approval date: June 17, 2009
Strength(s): 50MG [RLD]
Has a generic version of Cambia been approved?
No. There is currently no therapeutically equivalent version of Cambia available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cambia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Pharmaceutical compositions based on Diclofenae
Patent 6,974,595
Issued: December 13, 2005
Inventor(s): Reiner; Alberto & Reiner; Giorgio
Assignee(s): ProEthic Pharmaceuticals, Inc.
New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.Patent expiration dates:
- May 15, 2017✓
- May 15, 2017
Pharmaceutical compositions and methods of treatment based on diclofenac
Patent 7,482,377
Issued: January 27, 2009
Inventor(s): Reiner; Alberto & Reiner; Giorgio
Assignee(s): Kowa Pharmaceuticals America, Inc.
New pharmaceutical compositions for oral use containing diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.Patent expiration dates:
- May 15, 2017✓✓✓
- May 15, 2017
Diclofenac formulations and methods of use
Patent 7,759,394
Issued: July 20, 2010
Inventor(s): Reiner; Giorgio & Reiner; Alberto & Meyer; Andreas
Assignee(s): APR Applied Pharma Research SA
Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.Patent expiration dates:
- June 16, 2026✓✓✓
- June 16, 2026
Diclofenac formulations and methods of use
Patent 8,097,651
Issued: January 17, 2012
Inventor(s): Reiner; Giorgio & Reiner; Alberto & Meyer; Andreas
Assignee(s): APR Applied Pharma Research s.a.
Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.Patent expiration dates:
- June 16, 2026✓✓✓
- June 16, 2026
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- June 17, 2012 - NEW DOSAGE FORM
See also...
- Cambia Consumer Information (Drugs.com)
- Cambia Powder Packets Consumer Information (Wolters Kluwer)
- Cambia Consumer Information (Cerner Multum)
- Cambia Advanced Consumer Information (Micromedex)
- Diclofenac Consumer Information (Drugs.com)
- Diclofenac Consumer Information (Wolters Kluwer)
- Diclofenac Enteric-Coated Tablets Consumer Information (Wolters Kluwer)
- Diclofenac Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Diclofenac Immediate-Release Tablets Consumer Information (Wolters Kluwer)
- Diclofenac Potassium Powder Packets Consumer Information (Wolters Kluwer)
- Diclofenac Consumer Information (Cerner Multum)
- Diclofenac Advanced Consumer Information (Micromedex)
- Diclofenac Potassium AHFS DI Monographs (ASHP)
- Diclofenac Sodium AHFS DI Monographs (ASHP)
- Diclofenac epolamine AHFS DI Monographs (ASHP)
Thursday, 15 October 2009
Grifonimod
Grifonimod may be available in the countries listed below.
Ingredient matches for Grifonimod
Nimodipine
Nimodipine is reported as an ingredient of Grifonimod in the following countries:
- Chile
International Drug Name Search
Wednesday, 14 October 2009
Banex-LA
Generic Name: guaifenesin and phenylpropanolamine (gwye FEN e sin/fen ill proe pa NOLE a meen)
Brand Names: Ami-Tex LA, Banex-LA, Coldloc-LA, Dayquil Sinus Pressure and Congestion, Despec, Entex LA, Exgest LA, G-Vent, Guaifenex PPA 75, Guaivent, Guiatex LA, Naldecon-EX Pediatric, Nasahist LA, Phentex-LA, Phenylfenesin LA, Poly-Vent, Profen LA, Stamoist LA, Triaminic Expectorant, Vanex-LA
What is Banex-LA (guaifenesin and phenylpropanolamine)?
Guaifenesin is an expectorant. It is used to break up congestion and mucous to make breathing easier. Guaifenesin thins mucous, increases lubrication of the respiratory tract (lungs, nose and throat), and increases the removal of mucous.
Phenylpropanolamine is a decongestant. It constricts (shrinks) blood vessels (veins and arteries), which reduces swelling of mucous membranes in areas such as the nose and sinuses.
Guaifenesin and phenylpropanolamine is used to treat the symptoms of the common cold and of infections of the sinuses, lungs, and throat.
Phenylpropanolamine, an ingredient in this product, has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine.
Guaifenesin and phenylpropanolamine may also be used for purposes other than those listed in this medication guide.
What is the most important information I should know about Banex-LA (guaifenesin and phenylpropanolamine)?
Phenylpropanolamine, an ingredient in this product, has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine.
Drink plenty of extra fluids while taking this medication. Do not crush or chew the tablets. Swallow them whole or break them in half where they are scored to make them easier to swallow if needed.
Who should not take Banex-LA (guaifenesin and phenylpropanolamine)?
Do not take guaifenesin and phenylpropanolamine if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.
Before taking this medication, tell your doctor if you have
high blood pressure or any other type of heart disease,
diabetes,
a peripheral vascular disorder (poor circulation),
glaucoma or increased pressure in the eyes,
an overactive thyroid, or
difficulty urinating or an enlarged prostate.
You may not be able to take guaifenesin and phenylpropanolamine, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.
Guaifenesin and phenylpropanolamine is in the FDA pregnancy category C. This means that it is not known whether guaifenesin and phenylpropanolamine will harm an unborn baby. Do not take this medication without first talking to your doctor if you are pregnant. This medication passes into breast milk and may harm a nursing baby. Do not take this medication without first talking to your doctor if you are breast-feeding a baby. If you are over 65 years of age, you may be more likely to experience side effects from guaifenesin and phenylpropanolamine. You may require a lower dose of this medication. Guaifenesin and phenylpropanolamine has not been approved for use by children younger than 6 years of age.
How should I take Banex-LA (guaifenesin and phenylpropanolamine)?
Take guaifenesin and phenylpropanolamine exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.
Take each dose with a full glass of water. Increasing fluid intake during the day may help relieve congestion. Take guaifenesin and phenylpropanolamine with food if it causes stomach upset. Do not crush or chew the tablets. Swallow them whole or break them in half where they are scored to make them easier to swallow if needed. Store guaifenesin and phenylpropanolamine at room temperature away from moisture and heat.
What happens if I miss a dose?
Take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and take only the next regularly scheduled dose. Do not take a double dose of this medication.
What happens if I overdose?
Seek emergency medical attention.
Symptoms of a guaifenesin and phenylpropanolamine overdose include vomiting, high blood pressure (headache, redness of face, blurred vision), an irregular heartbeat, and numbness of the fingers or toes.
What should I avoid while taking Banex-LA (guaifenesin and phenylpropanolamine)?
Use caution when driving, operating machinery, or performing other hazardous activities. Guaifenesin and phenylpropanolamine may cause dizziness. If you experience dizziness, avoid these activities.
Banex-LA (guaifenesin and phenylpropanolamine) side effects
No serious side effects from guaifenesin and phenylpropanolamine are expected. Seek emergency medical attention if you experience an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives).
Other, less serious side effects may be more likely to occur. Continue to take guaifenesin and phenylpropanolamine and talk to your doctor if you experience
dizziness or headache;
nervousness, restlessness, or insomnia;
nausea or stomach upset; or
difficulty urinating.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
What other drugs will affect Banex-LA (guaifenesin and phenylpropanolamine)?
Do not take guaifenesin and phenylpropanolamine if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.
Heart medications such as methyldopa (Aldomet), reserpine (Serpalan, Serpasil), and guanethidine (Ismelin) may have decreased effects. Talk to your doctor before taking guaifenesin and phenylpropanolamine if you are taking any of these medications.
Do not take other over-the-counter cough, cold, allergy, diet, or sleep aids while taking guaifenesin and phenylpropanolamine without first talking to your doctor or pharmacist. Other medications may also contain guaifenesin, phenylpropanolamine, or other similar drugs. You may accidentally take too much of these medicines.
Drugs other than those listed here may also interact with guaifenesin and phenylpropanolamine. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.
More Banex-LA resources
- Banex-LA Side Effects (in more detail)
- Banex-LA Use in Pregnancy & Breastfeeding
- Banex-LA Drug Interactions
- Banex-LA Support Group
- 0 Reviews for Banex-LA - Add your own review/rating
Compare Banex-LA with other medications
- Cough and Nasal Congestion
Where can I get more information?
- Your pharmacist has additional information about guaifenesin and phenylpropanolamine written for health professionals that you may read.
What does my medication look like?
Guaifenesin and phenylpropanolamine is available with a prescription under several brand names. Ask your pharmacist any questions you have about this medication, especially if it is new to you.
Entex LA, 400 mg of guaifenesin and 75 mg of phenylpropanolamine--orange, scored tablets
Exgest LA, 400 mg of guaifenesin and 75 mg of phenylpropanolamine--white, oval-shaped, scored, long-acting tablets with blue speckles
Dura-Vent, 600 mg of guaifenesin and 75 mg of phenylpropanolamine--white, scored tablets
See also: Banex-LA side effects (in more detail)
Wednesday, 30 September 2009
Girolac
Girolac may be available in the countries listed below.
Ingredient matches for Girolac
Ketorolac
Ketorolac tromethamine (a derivative of Ketorolac) is reported as an ingredient of Girolac in the following countries:
- Italy
International Drug Name Search
Sunday, 27 September 2009
RFD Wormer
Dosage Form: FOR ANIMAL USE ONLY
RFD®
(pyrantel pamoate)
LIQUID
WORMER
Easy to administer.
Indications and Usage
For the removal of large roundworms (Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala) in dogs and puppies. The presence of these parasites should be confirmed by laboratory fecal exam. Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism.
RFD Liquid Wormer may also be used to prevent reinfestation of T. canis in puppies and adult dogs and in lactating bitches after whelping.
Shake Well Before Use
Active Ingredient: 2.27 mg of pyrantel base as pyrantel pamoate per mL.
Recommended Storage
Store below 30°C (86°F).
Warning
Keep out of reach of children.
Dosage and Administration
Administer 1 teaspoon (5 mL) for each 5 lb of body weight. To assure proper dosage, weigh animal prior to treatment. It is not necessary to withhold food prior to treatment. Dogs usually find this dewormer very palatable and will lick the dose from the bowl willingly. If there is reluctance to accept the dose, mix in a small quantity of dog food to encourage consumption. It is recommended that dogs maintained under conditions of constant exposure to worm infestation should have a follow-up fecal exam within 2–4 weeks after first treatment. If your dog looks or acts sick, consult your veterinarian before treatment.
For maximum control and prevention of reinfestation, it is recommended that puppies be treated at 2, 3, 4, 6, 8 and 10 weeks of age. Lactating bitches should be treated 2–3 weeks after whelping. Adult dogs kept in heavily contaminated quarters may be treated at monthly intervals to prevent T. canis reinfestation.
Distributed by:
Pfizer Animal Health
Div. of Pfizer Inc, NY, NY 10017
7985000
10229200
81551791
81607983, R.0
Made in USA
PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label
RFD®
(pyrantel pamoate)
LIQUID
WORMER
FOR PUPPIES AND DOGS
NADA #100-237, APPROVED BY FDA
Net Contents:
2 fl oz (60 mL)
Pfizer
| RFD WORMER pyrantel pamoate suspension | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NADA | NADA100237 | 06/03/1979 | |
| Labeler - Pfizer Animal Health (039055157) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Pfizer Animal Health | 039055157 | MANUFACTURE | |
Subscribe to:
Posts (Atom)